



1634

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weiniu GAN et al.

Art Unit: 1634

Serial No.: 09/805,455

Examiner: J. Fredman

Filed: March 14, 2001

Atty. Docket: CL001165

For: ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

Please charge the fee set forth in §1.17(p) to deposit account number 50-0970.

Furthermore, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: August 15, 2003

By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084

Substitution for form 1449B/PTO <h2 style="margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(use as many sheets as necessary)</i></p> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> Sheet 1 of 1 </div>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: right; padding: 5px;"><i>Complete if Known</i></th> </tr> <tr> <td style="width: 35%; padding: 5px;">Application Number</td> <td style="padding: 5px;">09/805,455</td> </tr> <tr> <td style="padding: 5px;">Filing Date</td> <td style="padding: 5px;">March 14, 2001</td> </tr> <tr> <td style="padding: 5px;">First Named Inventor</td> <td style="padding: 5px;">Weiniu GAN et al.</td> </tr> <tr> <td style="padding: 5px;">Group Art Unit</td> <td style="padding: 5px;">1634</td> </tr> <tr> <td style="padding: 5px;">Examiner Name</td> <td style="padding: 5px;">J. Fredman</td> </tr> <tr> <td style="padding: 5px;">Attorney Docket Number</td> <td style="padding: 5px;">CL001165</td> </tr> </table>	<i>Complete if Known</i>		Application Number	09/805,455	Filing Date	March 14, 2001	First Named Inventor	Weiniu GAN et al.	Group Art Unit	1634	Examiner Name	J. Fredman	Attorney Docket Number	CL001165
<i>Complete if Known</i>															
Application Number	09/805,455														
Filing Date	March 14, 2001														
First Named Inventor	Weiniu GAN et al.														
Group Art Unit	1634														
Examiner Name	J. Fredman														
Attorney Docket Number	CL001165														

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		Results of BLAST search of SEQ ID NO:2 against Derwent (FastAlert and GeneSeqP) and NCBI (pataa) protein patent databases on July 22, 2003.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.